Source: Annals of Oncology. Conference titles: European Society for Medical Oncology Congress - ESMO. Unidade: FMRP
Subjects: IMUNOLOGIA, METABOLISMO, GLICOSE
ABNT
SILVA, S. B et al. Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors. Annals of Oncology. Amterdam: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.annonc.2021.08.1377. Acesso em: 25 abr. 2026. , 2021APA
Silva, S. B., Wanderley, C. W. de S., Marin, J. F. G., Macedo, M. P. de, Nascimento, E. .C. T. do, Antonacio, F. F., et al. (2021). Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors. Annals of Oncology. Amterdam: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.annonc.2021.08.1377NLM
Silva SB, Wanderley CW de S, Marin JFG, Macedo MP de, Nascimento E .CT do, Antonacio FF, Cunha F de Q, Castro Jr. G de. Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors [Internet]. Annals of Oncology. 2021 ; 32 S846-S847.[citado 2026 abr. 25 ] Available from: https://doi.org/10.1016/j.annonc.2021.08.1377Vancouver
Silva SB, Wanderley CW de S, Marin JFG, Macedo MP de, Nascimento E .CT do, Antonacio FF, Cunha F de Q, Castro Jr. G de. Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors [Internet]. Annals of Oncology. 2021 ; 32 S846-S847.[citado 2026 abr. 25 ] Available from: https://doi.org/10.1016/j.annonc.2021.08.1377
